{
    "clinical_study": {
        "@rank": "72431", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who\n      have metastatic germ cell tumors that have not responded to cisplatin."
        }, 
        "brief_title": "Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin", 
        "completion_date": {
            "#text": "November 2001", 
            "@type": "Actual"
        }, 
        "condition": [
            "Ovarian Cancer", 
            "Testicular Germ Cell Tumor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Neoplasms, Germ Cell and Embryonal"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the efficacy of temozolomide in patients with cisplatin refractory\n      metastatic germ cell tumors. II. Determine the safety of this treatment in these patients.\n\n      OUTLINE: Patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for\n      a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study over 25 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed metastatic germ cell tumor Seminoma OR\n        Nonseminoma Measurable disease Abnormalities on radiograph OR Alpha fetoprotein greater\n        than 15 ng/mL OR Beta human chorionic gonadotropin greater than 2.2 mIU/L At least one\n        measurable disease site that has not received prior radiotherapy Refractory to prior\n        cisplatin and failed, not eligible for, or refused autologous bone marrow transplantation\n\n        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Karnofsky 70-100% Life\n        expectancy: At least 3 months Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil\n        count at least 1,000/mm3 Platelet count at lest 80,000/mm3 Hemoglobin at least 10 g/dL\n        Hepatic: Bilirubin no greater than 1.5 times normal Transaminases no greater than 1.5\n        times upper limit or normal (ULN) Alkaline phosphatase no greater than 3.0 times ULN\n        Renal: Creatinine no greater than 1.5 times ULN Other: No medical conditions that would\n        interfere with swallowing or cause excessive vomiting No second malignancy except basal\n        and squamous cell skin cancer Not pregnant or nursing Negative pregnancy test Fertile\n        patients must use effective barrier contraception\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See\n        Disease Characteristics Endocrine therapy: Not specified Radiotherapy: See Disease\n        Characteristics Surgery: Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "firstreceived_date": "July 5, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00006043", 
            "org_study_id": "00-010", 
            "secondary_id": [
                "CDR0000068058", 
                "NCI-G00-1817"
            ]
        }, 
        "intervention": {
            "intervention_name": "temozolomide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Temozolomide", 
                "Cisplatin", 
                "Dacarbazine"
            ]
        }, 
        "keyword": [
            "stage III malignant testicular germ cell tumor", 
            "recurrent malignant testicular germ cell tumor", 
            "stage IV ovarian germ cell tumor", 
            "recurrent ovarian germ cell tumor"
        ], 
        "lastchanged_date": "June 4, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-00010"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Trial of Temozolomide in Patients With Cisplatin-Refractory Germ Cell Tumors", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Robert J. Motzer, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2001", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00006043"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}